Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity

What impact will Trump’s US-UK trade deal have? How are Trump tariffs affecting US automakers? Why did the Federal Reserve hold interest rates steady? What is causing the surge in oil prices today? How will India-Pakistan tensions influence markets? Why is Netflix redesigning its streaming app? What does OpenAI’s new CEO appointment mean? How are tariffs reshaping global supply chains? Why is Disney expanding to the Middle East?

Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity

benzinga.com/25/05/45276127/novo-nordisks-wegovy-in-a-pill-delivers-big-166-average-weight-loss-over-20-for-one-third-of-patients

Novo Nordisk A/S (NYSE:NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables.
What Happened: On Wednesday, during Novo’s first quarter earnings…

This story appeared on benzinga.com, 2025-05-08 05:31:09.